Compare WVE & KD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WVE | KD |
|---|---|---|
| Founded | 2012 | 2020 |
| Country | Singapore | United States |
| Employees | N/A | 80000 |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.8B |
| IPO Year | 2015 | 2021 |
| Metric | WVE | KD |
|---|---|---|
| Price | $7.26 | $13.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 5 |
| Target Price | $30.25 | ★ $31.00 |
| AVG Volume (30 Days) | ★ 5.4M | 3.0M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 170.95 |
| EPS | N/A | ★ 0.77 |
| Revenue | $3,704,000.00 | ★ $15,057,000,000.00 |
| Revenue This Year | $0.34 | $3.96 |
| Revenue Next Year | $83.30 | $0.41 |
| P/E Ratio | ★ N/A | $16.66 |
| Revenue Growth | ★ 149.43 | N/A |
| 52 Week Low | $5.02 | $10.10 |
| 52 Week High | $21.73 | $43.74 |
| Indicator | WVE | KD |
|---|---|---|
| Relative Strength Index (RSI) | 30.10 | 48.22 |
| Support Level | $6.94 | $12.07 |
| Resistance Level | $8.29 | $13.81 |
| Average True Range (ATR) | 0.75 | 0.51 |
| MACD | -0.50 | 0.31 |
| Stochastic Oscillator | 26.85 | 88.49 |
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in Australia / New Zealand, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.